Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.

Genes - 8 May 2023

Bikhchandani Mihir, Amersi Farin, Hendifar Andrew, Gangi Alexandra, Osipov Arsen, Zaghiyan Karen, Atkins Katelyn, Cho May, Aguirre Francesca, Hazelett Dennis, Alvarez Rocio, Zhou Lisa, Hitchins Megan, Gong Jun

Abstract excerpt

Colon cancer with high microsatellite instability is characterized by a high tumor mutational burden and responds well to immunotherapy. Mutations in polymerase ɛ, a DNA polymerase involved in DNA replication and repair, are also associated with an ultra-mutated phenotype. We describe a case where a patient with POLE-mutated and hypermutated recurrent colon cancer was treated with pembrolizumab. Treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Colorectal Cancer Treatments and Studies

Share to Genetic factors in colorectal cancer

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 37239414
DOI: 10.3390/genes14051054
PMCID: PMC10218075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.PMID 37239414Read ↗

Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.Semantic proximity Read ↗

PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation.Semantic proximity Read ↗

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.Semantic proximity Read ↗

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Semantic proximity Read ↗

The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome.Semantic proximity Read ↗

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.Semantic proximity Read ↗

Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε ( POLE )Semantic proximity Read ↗

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.Semantic proximity Read ↗

POLE/POLD1 mutation and tumor immunotherapy.Semantic proximity Read ↗

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.